Definium Therapeutics (DFTX) CMO Daniel Karlin Receives 100,000-Share Award

What Happened Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), was granted 100,000 shares on 2026-08-12 as an award (transaction code A) at $0.00 per share (total cash consideration $0). This grant represents the second tranche of performance share units (PSUs) previously granted effective March 12, 2025, and the award remains contingent on continued employment and achievement of specified clinical and regulatory milestones.

Key Details

• Transaction date: 2026-08-12; transaction type: Award/Grant (Code A).
• Shares granted: 100,000; price per share: $0.00; total cash paid: $0.
• Shares owned after transaction: Not specified in the filing.
• Footnote: These shares are the second tranche of PSUs (granted March 12, 2025) and vest only if Karlin remains employed through March 12, 2028 and certain clinical/regulatory milestones are met.
• Filing timeliness: Report filed on 2026-08-12 (no late filing indicated).
• No 10b5-1 plan, tax withholding, or sale reported in this filing.

Context Performance share units are contingent awards that convert to common shares only upon meeting defined performance targets and continued employment; they are not an immediate purchase or sale of stock. Such awards are common in executive compensation to align management incentives with long-term company milestones and do not by themselves indicate an intent to buy or sell shares.